TRIM33 and dermatomyositis: Patients harboring anti-nucleosome remodeling-histone deacetylase complex (Mi2), anti-melanoma differentiation-associated protein 5 (MDA5), anti-transcriptional intermediary factor 1 γ (TIF1-γ), anti-small ubiquitin-like modifier activating enzyme (SAE), or anti-nuclear matrix protein 2 (NXP2) autoantibodies present a clinical phenotype of dermatomyositis.